OGN · Organon & Co. · Webcasts, Transcripts & Audio
$13.90
+0.00 (+0.00%)
At close · Nov 17
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$3.65B
Shares
262.62M
Volume · Nov 17
4.16M
Avg daily vol (3M)
2.71M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Organon & Co. Webcasts
Earnings calls, investor updates, investor days and conferences for Organon & Co. (OGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Annual General Meeting
Investor event
2026-06-09
Organon & Co. (OGN) June 9, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Organon & Co. (OGN) Q1 2026 Earnings Call
Revenue
$1.46B
▼ 3.5% YoY Diluted EPS
$0.55
▲ 66.7% YoY Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Balanced tone
Established brands / respiratory reset
Nexplanon headwinds
Flat 2026 outlook
Revenue
$1.51B*
▼ 5.3% YoY Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
Balanced tone
Nexplanon outlook
Business development and pipeline
Leadership transition and CEO search
Revenue
$1.60B
▲ 1.3% YoY Diluted EPS
$0.61
▼ 55.8% YoY Gross margin
53.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Positive tone
Vtama growth and access
Nexplanon 5-year indication and U.S. funding risk
Women's Health franchise
Revenue
$1.59B
▼ 0.8% YoY Diluted EPS
$0.56
▼ 25.3% YoY Gross margin
54.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Organon & Co. (OGN) Q1 2025 Earnings Call Transcript
Positive tone
Vtama launch in atopic dermatitis
Guidance affirmation and free cash flow
Tariff exposure and supply chain
Revenue
$1.51B
▼ 6.7% YoY Diluted EPS
$0.33
▼ 57.7% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Confident tone
Vtama and Dermavant Launch
Nexplanon Growth and 5-Year Indication
Atozet Loss of Exclusivity Headwind
Revenue
$1.59B*
▼ 0.4% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
Confident tone
Revenue Growth and Guidance
VTAMA / Dermavant Acquisition
Adjusted EBITDA Margin
Revenue
$1.58B
▲ 4.1% YoY Diluted EPS
$1.38
▲ 500% YoY Gross margin
58.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Organon & Co. (OGN) Q2 2024 Earnings Call Transcript
Confident tone
Biosimilars franchise momentum
China market dynamics
Full year 2024 guidance and EBITDA margin
Revenue
$1.61B
▼ 0.1% YoY Diluted EPS
$0.75
▼ 21.1% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Organon & Co. (OGN) Q1 2024 Earnings Call Transcript
Confident tone
Women's Health Franchise (NEXPLANON)
Biosimilars Franchise
Established Brands and Migraine Assets
Revenue
$1.62B
▲ 5.5% YoY Diluted EPS
$0.78
▲ 13% YoY Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Organon & Co. (OGN) Q4 2023 Earnings Call Transcript
Confident tone
Revenue growth and 2024 guidance
Women's Health franchise
Free cash flow and leverage
Revenue
$1.60B*
▲ 7.6% YoY Gross margin
57.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Organon & Co. (OGN) Q3 2023 Earnings Call Transcript
Revenue
$1.52B
▼ 1.2% YoY Diluted EPS
$0.23
▼ 74.2% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Organon & Co. (OGN) Q2 2023 Earnings Call Transcript
Revenue
$1.61B
▲ 1.5% YoY Diluted EPS
$0.95
▲ 3.3% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Organon & Co. (OGN) Q1 2023 Earnings Call Transcript
Revenue
$1.54B
▼ 1.9% YoY Diluted EPS
$0.69
▼ 49.3% YoY Gross margin
62.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Organon & Co. (OGN) Q4 2022 Earnings Call Transcript
Revenue
$1.49B*
▼ 7.4% YoY Gross margin
60.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Organon & Co. (OGN) Q3 2022 Earnings Call Transcript
Revenue
$1.54B
▼ 3.9% YoY Diluted EPS
$0.89
▼ 29.9% YoY Gross margin
64.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Organon & Co. (OGN) Q2 2022 Earnings Call Transcript
Revenue
$1.58B
▼ 0.6% YoY Diluted EPS
$0.92
▼ 45.2% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Organon & Co. (OGN) Q1 2022 Earnings Call Transcript
Revenue
$1.57B
▲ 4.1% YoY Diluted EPS
$1.36
▼ 13.9% YoY Gross margin
64.2%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Organon & Co. (OGN) Q4 2021 Earnings Call Transcript
Revenue
$1.60B*
▼ 0.6% YoY Gross margin
62.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Organon & Co. (OGN) Q3 2021 Earnings Call Transcript
Revenue
$1.60B
▼ 0.8% YoY Diluted EPS
$1.27
▼ 41.2% YoY Gross margin
61.9%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Organon & Co. (OGN) Q2 2021 Earnings Call Transcript
Revenue
$1.59B
▲ 4.5% YoY Diluted EPS
$1.68
▼ 21.5% YoY Gross margin
63.4%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–21 of 21 webcasts
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
642 filings
554 filers
Visit website
Investor relations